336628-65-0

Usage

Uses

Used in Pharmaceutical Industry:
1-Methoxymethoxy-2-(trifluoromethyl)benzene is used as a solvent in the production of pharmaceuticals for its ability to dissolve a variety of substances, facilitating the manufacturing process of various medications.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Methoxymethoxy-2-(trifluoromethyl)benzene serves as a solvent, aiding in the formulation of agricultural chemicals that require its solubility properties to ensure effective application and performance.
Used as a Starting Material in Organic Synthesis:
1-Methoxymethoxy-2-(trifluoromethyl)benzene is utilized as a starting material in the synthesis of other organic compounds, contributing to the creation of new chemical entities for various applications across different industries.

Upstream product

• 444-30-4 2-(trifluoromethyl)phenol 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 368422-26-8 2-methoxymethoxy-3-(trifluoromethyl)benzoic acid 
• 336628-66-1 2-(methoxymethoxy)-3-(trifluoromethyl)benzaldehyde 
• 336628-67-2 2-hydroxy-3-(trifluoromethyl)benzaldehyde 
• 251300-32-0 2-hydroxy-3-(trifluoromethyl)benzoic acid 
• 1268725-95-6 (S)-2-((2-(hydroxydiphenylmethyl)pyrrolidin-1-yl)methyl)-6-(trifluoromethyl)phenol 
• 1285572-57-7 3-(3-cyano-4-hydroxy-5-trifluoromethylbenzoyl)-1,1-dioxo-1,2-dihydro-3H-1,3-benzothiazole 
• 251300-30-8 5-bromo-2-hydroxy-3-(trifluoromethyl)benzaldehyde 
• 1285573-52-5 5-bromo-2-methoxy-3-trifluoromethylbenzaldehyde 
• 1285573-58-1 5-bromo-1-diethoxymethyl-2-methoxy-3-trifluoromethylbenzene 
• 1285573-63-8 3-formyl-4-methoxy-5-trifluoromethylbenzoic acid 
• 1285573-65-0 5-cyano-4-methoxy-3-trifluoromethylbenzoic acid 
• 1285573-68-3 3-cyano-4-methoxy-5-trifluoromethylbenzoyl chloride 
• 1285573-71-8 3-(3-cyano-4-methoxy-5-trifluoromethylbenzoyl)-2,3-dihydro-1,3-benzothiazole 
• 1285573-75-2 3-(3-cyano-4-methoxy-5-trifluoromethylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 

Relevant academic research and scientific papers

Silylaryl Halides Can Replace Triflates as Aryne Precursors

Silylaryl bromides and iodides can be prepared in one step from commercially available starting materials. Arynes can be generated from these compounds under conditions nearly identical to those employed for silylaryl triflates. Three distinct transformat

ASK1 INHIBITING AGENTS

Provided are compounds of Formulas (I'), (I), (II') and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Synthesis of obscuraminol A using an organocatalyzed enantioselective Henry reaction

The first synthesis of the polyunsaturated amino alcohol natural product obscuraminol A is reported. This stereoselective synthesis was based on an anti- and enantioselective organocatalyzed Henry reaction followed by a chemoselective SmI2-mediated reduction that affected only the nitro-group of the Henry product. These efforts yielded obscuraminol A where the configuration of the all-Z skipped double bonds was conserved from the starting material, i.e. the ethyl ester of (all-Z)-eicosa-5,8,11,14,17-pentaenoic acid. Our synthesis confirmed the reported structure of obscuraminol A.

NOVEL PHENOL DERIVATIVE

Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt t

Highly enantioselective henry reactions in water catalyzed by a copper tertiary amine complex and applied in the synthesis of (S)-N-trans-feruloyl octopamine

It's in the water! A new copper tertiary amine complex was prepared and applied in asymmetric Henry reactions in water and in the short synthesis of (S)-N-trans-feruloyl octopamine. This catalytic system provided an approach to the enantioselective Henry reaction of aldehydes with hydroxyl substituents (see graphic).

TRPV1 ANTAGONISTS

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Synthesis and evaluation of novel inhibitors of pim-1 and pim-2 protein kinases

The Pim protein kinases are frequently overexpressed in prostate cancer and certain forms of leukemia and lymphoma. 5-(3-Trifluoromethylbenzylidene) thiazolidine-2,4-dione (4a) was identified by screening to be a Pim-1 inhibitor and was found to attenuate the autophosphorylation of tagged Pim-1 in intact cells. Although 4a is a competitive inhibitor with respect to ATP, a screen of approximately 50 diverse protein kinases demonstrated that it has high selectivity for Pim kinases. Computational docking of 4a to Pim-1 provided a model for lead optimization, and a series of substituted thiazolidine-2,4-dione congeners was synthesized. The most potent new compounds exhibited IC 50s of 13 nM for Pim-1 and 2.3 μM for Pim-2. Additional compounds in the series demonstrated selectivities of more than 2500-fold and 400-fold for Pim-1 or Pim- 2, respectively, while other congeners were essentially equally potent toward the two isozymes. Overall, these compounds are new Pim kinase inhibitors that may provide leads to novel anticancer agents.

Chiral zirconium catalysts using multidentate BINOL derivatives for catalytic enantioselective Mannich-type reactions; ligand optimization and approaches to elucidation of the catalyst structure

Catalytic enantioselective Mannich-type reactions of silicon enolates with aldimines were investigated using chiral zirconium catalysts prepared from Zr(OtBu)4, N-methylimidazole, and newly designed multidentate BINOL derivatives. Th

The synthesis and use in asymmetric epoxidation of metal salen complexes derived from enantiopure trans-cyclopentane- and cyclobutane-1,2-diamine

A complete synthesis of enantiopure trans-cyclopentane-1,2-diamine and trans-cyclobutane-1,2-diamine is described. These diamines have been used as components of novel chiral salen ligands whose chromium and manganese complexes were then evaluated as oxygen transfer agents in the asymmetric epoxidation of alkenes.